Abbott Labs' Earnings Sink in Q2 but Still Trounce Wall Street Estimates

Abbott Labs' Earnings Sink in Q2 but Still Trounce Wall Street Estimates

Abbott Labs (NYSE: ABT) suspended its full-year 2020 guidance in April because of uncertainty about the COVID-19 pandemic. Investors found out whether or not Abbott continued to win on Thursday with the healthcare giant announcing its second-quarter results before the market opened. Here are the highlights from Abbott's Q2 update.